Plain-English translation of NCT07600554 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new diagnostic imaging agent called 68Ga-OncoACP3, which is a radioactive tracer that can help doctors find prostate cancer cells in the body using PET/CT scans. The medication works by targeting a specific protein (ACP3) that is found on prostate cancer cells. Researchers want to understand how safe this medication is and how it moves through the body.
Some men with prostate cancer need better imaging tools to find where their cancer has spread or returned, especially when other standard imaging tests don't show clear results. This medication could help doctors locate cancer more accurately and plan better treatment.
You will receive a single injection of the radioactive medication through your vein, then undergo a series of PET/CT imaging scans to see how the medication moves through your body and which cancer cells it detects. You will also provide blood and urine samples at different time points. The study involves multiple visits to complete the imaging scans and laboratory tests, allowing doctors to measure how safe the medication is and how your body processes it.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
Italy
Phase
Safety & dosing
Sponsor
Philogen S.p.A.
Enrollment target
~20 participants
Started
May 2026
Primary completion
October 2026
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in October 2026.